The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
92
Rapid metabolizer will receive 1mg IV Granisetron
Poor or normal metabolizers will receive 4mg Ondansetron IV
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Episodes of Postoperative Nausea
The total number count of post operative nausea episodes were determined by nursing documentation or by treatment with rescue antinausea medication.
Time frame: 0-48 hours post bariatric surgery
Episodes of Postoperative Vomiting
The total number count of post operative vomiting episodes were determined by nursing documentation or by treatment with rescue antinausea medication.
Time frame: 0-48 hours post bariatric surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.